Publications by authors named "Clelia Favary"
Background: Cardiovascular comorbidities are not contraindications of bevacizumab for metastatic colorectal cancer.
Objective: We aimed to evaluate the impact of cardiovascular comorbidities before bevacizumab treatment on overall survival and cardiovascular safety in older patients with metastatic colorectal cancer.
Methods: A 2009-2015 cohort of patients with metastatic colorectal cancer aged ≥ 65 years administered first-line bevacizumab was extracted from the French healthcare reimbursement claims database.
Article Synopsis
- The study aimed to compare cancer risks in multiple sclerosis patients who used exclusive immunosuppressants (IS) versus immunomodulators (IM) from 2008 to 2014, using data from the French claims database.
- Among 28,720 patients, 407 developed cancer, showing a significant 37% higher risk for those using IS compared to IM, particularly within the first 2 years of use.
- However, the study found no increased cancer risk associated with prolonged use of IS solely prescribed for MS, suggesting no causal link between these medications and cancer for that duration.
Background: Topical calcineurin inhibitors are used off label in the treatment of vitiligo, and there is a lack of placebo-controlled, blinded studies to support their use.
Objective: This study aimed to compare the efficacy of tacrolimus 0.1% ointment with that of the vehicle for repigmentation in adult patients with facial vitiligo.
Background: Although the efficacy and safety of existing therapies of heart failure (HF) have been demonstrated in clinical trials, little is known about the treatment patterns in clinical practice, especially in France.
Objectives: To describe the treatment initiation patterns and the subsequent treatment changes among HF patients, in the first year following an incident hospitalization for HF, in a French real-world setting.
Methods: A cohort of patients aged ≥ 40 years, with an incident hospitalization for HF between 01/01/2008 and 31/12/2013, was identified in the 1/97th permanent random sample of the French nationwide claims database and followed 1 year.